Company Overview
Snapshot
Founded in January 2022 by Moshe Elkabets and Angel Porgador, ImmuniQ operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on customer development for its personalized immuno-oncology treatment solutions.
Business overview
ImmuniQ is a Health Tech & Life Sciences company specializing in personalized immuno-oncology treatments. The company has developed a proprietary immune checkpoint artificial reporter (IcAR) technology designed to quantify the functional tumor response to immunotherapy drugs. This technology measures the actual surface activity of a patient’s cancer cells, aiming to enable more effective and tailored treatment strategies for individuals. ImmuniQ operates within the pharmaceuticals, drug discovery, and immunology sectors, serving the healthcare and life sciences markets.
Log in to access full profile ›Company Intelligence Q&A
- What is ImmuniQ's core technology?
- ImmuniQ has developed an immune checkpoint artificial reporter (IcAR) technology. This method quantifies the actual and functional tumor response to immunotherapy drugs by measuring the surface activity of a patient’s cancer cells.
- When was ImmuniQ founded?
- ImmuniQ was founded in January 2022.
- Who are the founders of ImmuniQ?
- ImmuniQ was co-founded by Moshe Elkabets and Angel Porgador.
- What problem does ImmuniQ aim to solve?
- ImmuniQ aims to enable more effective and personalized treatment for cancer patients by providing a method to quantify the actual and functional tumor response to immunotherapy drugs.
- In which sector does ImmuniQ primarily operate?
- ImmuniQ primarily operates in the Health Tech & Life Sciences sector, with a focus on pharmaceuticals, drug discovery, and immunology.